The Valley Desk

NCT04233879 · Interventional trial

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

Overall registry status Completed

Phase 3

Conditions HIV-1 Infection

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov